Role of aripiprazole in treating mood disorders

Expert Review of Neurotherapeutics

Volumn 6, Issue 12, 2006, Pages 1777-1783

  García Amador, Margarita ^b   Pacchiarotti, Isabella ^b   Valentí, Marc ^b   Sanchez, Raul F ^b   Goikolea, Jose M ^b   Vieta, Eduard ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Aripiprazole; Bipolar disorder; Mood disorders; Unipolar depression

Indexed keywords

ARIPIPRAZOLE; FLUOXETINE; HALOPERIDOL; OLANZAPINE; PLACEBO; ZIPRASIDONE;

AGITATION; AGRANULOCYTOSIS; AKATHISIA; ANXIETY; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOMANIA; LONG TERM CARE; MAJOR DEPRESSION; MANIA; MOOD DISORDER; NAUSEA; NERVOUSNESS; NEUROLEPTIC MALIGNANT SYNDROME; PSYCHOMOTOR DISORDER; QT PROLONGATION; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; TARDIVE DYSKINESIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MOOD DISORDERS; PHYSICIAN'S PRACTICE PATTERNS; PIPERAZINES; PRACTICE GUIDELINES; QUINOLONES; TREATMENT OUTCOME;

EID: 33845908998     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.12.1777     Document Type: Review

References (36)

1. Kinghorn WA, McEvoy JP. Aripiprazole: pharmacology, efficacy, safety and tolerability. Expert Rev. Neurother. 5(3), 297-307 (2005). • Good review of the pharmacology of aripiprazole.
2. Davies MA, Sheffler DJ 3rd, Roth BL. Aripiprazole: a novel atypical antipsychotic drug with a unique robust pharmacology. CNS Drug Rev. 10(4), 317-336 (2004).
3. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry 156, 286-293 (1999).
4. Kapur SJ, Zipursky R, Jones C, Houle S. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double blind PET study of first-episode schizophrenia. Am. J. Psychiatry 157, 514-520 (2000).
5. Hirose T, Uwahodo Y, Yamada S et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J. Psychopharmacol. 18(3), 375-383 (2004).
6. Lyseng-Williamson KA, Perry CM. Aripripazole in acute mania associated with bipolar I disorder. CNS Drugs 18(6), 367-376 (2004).
7. Grunder G, Carlson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch. Gen. Psychiatry 60, 74-77 (2003). •• Excellent overview of mechanisms of antipsychotic action and the potentialities of partial agonism, as opposed to full antagonism.
8. Reckless G, Natesan S, Parker J et al. Dissociation between blockade and functional antagonism of D2 receptors - comparing aripiprazole to other typical and atypical antipsychotics in animal models. Schizophrenia Bull. 31(2), 309 (2005).
9. Citrome L, Josiassen R, Bark N, Salazar DE, Mallikaarjun S. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J. Clin. Pharmacol. 45(1), 89-93 (2005). • In the absence of controlled trials on the combination of aripiprazole with lithium or valproate, this article provides a pharmacokinetic background and rationale for their use together.
10. Vieta E. Atypical antipsychotics in mood disorders. Curr. Opin. Psychiatry 16, 23-27 (2003).
11. Tohen M, Vieta E, Calabrese J et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry 60(11), 1079-1088 (2003). • First randomized trial of an atypical antipsychotic in bipolar depression.
12. Calabrese JR, Keck PE Jr, McFadden W et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am. J. Psychiatry. 162(7), 1351-1360 (2005). •• Trial showing robust response to an atypical antipsychotic in bipolar depression.
13. Thase M, McCoy R, Chang W, MacFadden W. Efficacy of quetiapine monotherapy in bipolar depression: a confirmatory, placebo-controlled study (the BOLDER II study). Presented at: The 159th APA Annual Meeting, Toronto, Canada, May 20-25 (2006).
14. Keck PE Jr, Marcus R, Tourkodimitris S et al. Placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am. J. Psychiatry 160(9), 1651-1658 (2003). •• First trial indicating that aripiprazole has antimanic properties.
15. Sachs G, Sanchez R, Marcus R et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J. Psychopharmacol. 20(4), 536-546 (2006).
16. Vieta E, Bourin M, Sanchez R et al. Effectiveness of aripripazole vs haloperidol in acute bipolar mania: double-blind, randomized, comparative 12-week trial. Br. J. Psychiatry 187, 235-242 (2005). • First randomized, comparative trial of a dopamine partial agonist and a powerful dopamine antagonist.
17. Vieta E, Goikolea JM. Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disord. 7(Suppl. 4), 21-33 (2005). • Update on the use of novel antipsychotics in mania and beyond.
18. Keck PE Jr, Calabrese JR, Mc Quade RD et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J. Clin. Psychiatry 67(4), 626-637 (2006).
19. Vieta E. Maintenance therapy for bipolar disorder: current and future management options. Expert Rev. Neurother. 4(Suppl. 2), 35-42 (2004). • Summary of the available data on the use of second-generation antipsychotic drugs, including aripiprazole, in the long-term treatment of bipolar disorder.
20. Brugue E, Vieta E. Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications. Prog. Neuropsychopharmacol. Biol. Psychiatry (2006) (Epub ahead of print). • Challenging review on the potential antidepressant actions of second-generation antipsychotic drugs, emphasizing the role of dopamine in the treatment of bipolar depression.
21. Yatham LN, Goldstein JM, Vieta E et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J. Clin. Psychiatry 66(Suppl. 5), 40-48 (2005).
22. Ketter TA, Wang PW, Chandler RA, Culver JL, Alarcon AM. Adjunctive aripiprazole in treatment-resistant bipolar depression. Ann. Clin. Psychiatry 18(3), 169-172 (2006).
23. Vieta E. Bipolar mixed states and their treatment. Expert Rev. Neurother. 5, 63-68 (2005).
24. Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J. Clin. Psychiatry 66, 1216-1220 (2005). • One of the few available studies suggesting potential antidepresant activity for aripiprazole.
25. Papakostas GI, Petersen TJ, Kinrys G et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J. Clin. Psychiatry 66, 1326-1330 (2005).
26. Barbee JG, Conrad EJ, Jamhour NJ. Aripiprazole augmentation in treatment-resistant depression. Ann. Clin. Psychiatry 16, 189-194 (2004).
27. Biederman J, McDonnell MA, Wozniack J et al. Aripripazole in the treatment of pediatric bipolar disorder: a systematic chart review. CNS Spectr. 10(2), 141-148 (2005).
28. Barzman DH, DelBello MP, Kowatch RA et al. The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review. CNJ Child Adolesc. Psychopharmacol. 14(4), 593-600 (2004). • First preliminary data available on the potential use of dopamine partial agonists in children and adolescents with mood disorders.
29. Potkin SG, Saha AR, Kujawa MJ et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 60, 681-690 (2003).
30. Kane JM, Carson WH, Saha AR et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry 63, 763-771 (2002).
31. Kasper S, Lerman MN, McQuade RD et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int. J. Neuropsychopharmacol. 6(4), 325-337 (2003).
32. Casey D, L'Italien GJ, Cislo P. Comparative one year incidence/worsening of metabolic syndrome among patients treated with olanzapine vs aripiprazole. Schizophrenia Bull. 31(2) 343-350 (2005).
33. McQuade RD, Stock E, Marcus R et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J. Clin. Psychiatry 65(Suppl. 18), 47-56 (2004).
34. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27, 596-601 (2004). • Important document dealing with weight gain, diabetes, metabolic syndrome and related issues as potential side effects of antipsychotic therapy.
35. Awad AG, Voruganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 18(13), 877-893 (2004).
36. Chakraborty N, Johnston T. Aripiprazole and neuroleptic malignant syndrome. Int. Clin. Psychopharmacol. 19(6), 351-353 (2004).